Reducing potential overuse of dementia drugs could lead to considerable savings

Reducing potential overuse of dementia drugs could lead to considerable savings

Collection:
Health Policy and Services Research
Series Title(s):
Insight on the issues (AARP Public Policy Institute)
Author(s):
Carter, Elizabeth A., author
Purvis, Leigh, author
Contributor(s):
AARP (Organization), issuing body.
Public Policy Institute (AARP (Organization)), issuing body.
Publication:
Washington, DC : AARP Public Policy Institute, August 2018
Language(s):
English
Format:
Text
Subject(s):
Dementia -- drug therapy
Dementia -- economics
Drug Costs
Inappropriate Prescribing -- economics
Aged
Cholinesterase Inhibitors -- economics
Cholinesterase Inhibitors -- therapeutic use
Cost Savings
Drug Therapy, Combination
Memantine -- economics
Memantine -- therapeutic use
Humans
United States
Genre(s):
Technical Report
Abstract:
Dementia medications typically provide modest, short-term benefits and have no proven effectiveness beyond one year of use. Nevertheless, our findings indicate that some adults with dementia remained on these drugs for as long as a decade, increasing the potential for adverse health outcomes and costing patients and insurers nearly $20,000. As much as 90 percent of this spending occurred after drug treatment was no longer supported by clinical evidence.
Copyright:
Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY-NC-ND license. (More information)
Extent:
1 online resource (1 PDF file (6 pages))
Illustrations:
Illustrations
NLM Unique ID:
101743455 (See catalog record)
Permanent Link:
http://resource.nlm.nih.gov/101743455